Review
Pharmacology & Pharmacy
Lijun Wang, Heng Yin, Liling Yang, Fenglian Zhang, Song Wang, Dan Liao
Summary: Roxadustat significantly improves hemoglobin, transferrin, and total iron binding capacity in patients with chronic kidney disease. After treatment, serum iron levels are significantly increased in the dialysis group and have no significant change in the non-dialysis group. Hepcidin, ferritin, and transferrin saturation are significantly reduced in the non-dialysis group. The short-term safety of Roxadustat is comparable to the comparison group.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Qiyan Zheng, Yahui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yu Ning Liu, Wei Jing Liu
Summary: Daprodustat showed significant efficacy in treating anemia of chronic kidney disease patients, with no serious adverse events observed. It demonstrated favorable outcomes compared to placebo and rhEPO in terms of hemoglobin levels.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Transplantation
Qiyan Zheng, Huisheng Yang, Xinwen Fu, Yishan Huang, Ruojun Wei, Yahui Wang, Yu Ning Liu, Wei Jing Liu
Summary: The meta-analysis found that roxadustat was effective in increasing hemoglobin levels in CKD patients and had a comparable safety profile to placebo and epoetin alfa. The findings support the use of roxadustat for the treatment of anemia in patients with CKD.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Review
Pharmacology & Pharmacy
Limei Xiong, Hui Zhang, Yannan Guo, Yue Song, Yuhong Tao
Summary: Vadadustat appears to be a safe and effective treatment for anemia in CKD patients, improving Hb levels and promoting iron utilization. Compared to placebo, it significantly reduces levels of hepcidin and ferritin and increases iron-binding capacity. However, compared to placebo or darbepoetin alfa, it may increase the risk of nausea and diarrhea.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Chao Liu, Zhangning Fu, Jiawei Jiang, Kun Chi, Xiaodong Geng, Zhi Mao, Chengcheng Song, Guannan Sun, Quan Hong, Guangyan Cai, Xiangmei Chen, Xuefeng Sun
Summary: The study found that the use of roxadustat is safe in CKD patients. In treating anemia in non-dialysis-dependent CKD patients, oral roxadustat was more effective than placebo; while in dialysis-dependent CKD patients, it was comparable to ESA.
FRONTIERS IN MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Zhangning Fu, Xiaodong Geng, Kun Chi, Chengcheng Song, Di Wu, Chao Liu, Quan Hong
Summary: This meta-analysis investigated the efficacy and safety of daprodustat, a novel HIF-PHI, in the treatment of chronic kidney disease (CKD)-related anemia. The results showed that daprodustat was noninferior to rhEPO in correcting anemia in both nondialysis-dependent and dialysis-dependent CKD patients. It also had a better effect on optimizing iron metabolism in dialysis-dependent CKD patients. However, further research is needed to evaluate the therapeutic effect of daprodustat due to the limited number of included studies.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Wenlin Liu, Lili Li, Xuemei Zhang, Haonan Dong, Miaomiao Lu
Summary: Veverimer is effective in increasing bicarbonate levels and improving physical function in CKD patients with metabolic acidosis, compared to placebo, with similar safety profiles. Further research is needed to compare long-term veverimer use with traditional alkali therapy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Ming-Zhu Zhang, Wujisiguleng Bao, Qi-Yan Zheng, Ya-Hui Wang, Lu-Ying Sun
Summary: The meta-analysis validates the clinical efficacy and safety of finerenone in patients with CKD. Finerenone demonstrated significant improvements in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR), leading to renal and cardiovascular benefits. However, the risk of hyperkalemia was higher in the finerenone group compared to the placebo group, while adverse events were similar.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Xiaohong Chen, Lifang Feng, Hui Yao, Luhong Yang, Yuan Qin
Summary: The meta-analysis found that diazoxide has potential efficacy in the management of hyperinsulinemic hypoglycemia, but also comes with some side effects that require careful monitoring. Further large-scale studies, such as randomized controlled trials, may be necessary in the future to gather more evidence.
Review
Cardiac & Cardiovascular Systems
Tae-Min Rhee, So-Ryoung Lee, Eue-Keun Choi, Seil Oh, Gregory Y. H. Lip
Summary: This study compared the efficacy and safety of oral anticoagulants in atrial fibrillation patients with renal impairment using pairwise and network meta-analysis. The results showed that DOACs, particularly apixaban and edoxaban, had superior efficacy and safety compared to warfarin. Apixaban was associated with the lowest risk of major bleeding in patients with advanced CKD.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Oncology
Mengdi Xia, Tong Liu, Dongming Chen, Ying Huang
Summary: This meta-analysis included 238 patients from 11 single-center, non-randomized, uncontrolled studies. The results showed that RDN may be effective and safe for treating CKD patients with hypertension, with significant reductions in blood pressure and urinary albumin-to-creatinine ratio observed after the procedure. Further well-designed randomized controlled trials are needed to confirm these findings and assess the impact on clinical outcomes.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2021)
Review
Integrative & Complementary Medicine
Wei Zhang, Jun Li, Pan Yang, Gaoqiang Wang, Yanli Yue, Yuanfang Zhong, Hanyin Liu, Dingkun Gui, Youhua Xu, Niansong Wang
Summary: This meta-analysis evaluated the effects of Salvia miltiorrhiza or its extracts Salvianolate and Tanshinone on chronic kidney disease (CKD). The results showed that these treatments had potential impacts in improving kidney functions and delaying CKD progression without obvious adverse effects. However, further clinical studies are needed to determine the underlying effects.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
(2022)
Review
Urology & Nephrology
Qianwei Zuo, Taizhong Wang, Lirong Zhu, Xiao Li, Qi Luo
Summary: This study evaluated the efficacy of ferumoxytol compared to conventional iron supplement formulations in chronic kidney disease patients. The results showed that ferumoxytol had positive effects on hemoglobin levels, ferritin levels, and treatment related adverse events in these patients.
Article
Urology & Nephrology
Kuan-Ting Chen, Yi-No Kang, Yen-Chung Lin, I-Lin Tsai, Wei-Chiao Chang, Te-Chao Fang, Mai-Szu Wu, Chih-Chin Kao
Summary: Mineralocorticoid receptor antagonists may reduce cardiovascular and all-cause mortality in patients with kidney failure without significantly increasing the risk of hyperkalemia. However, there was no significant reduction in nonfatal cardiovascular events and stroke, as well as no significant improvement in blood pressure and cardiac performance parameters.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Review
Urology & Nephrology
Qian Zeng, Yuanlong Zhong, Xiqiu Yu
Summary: This study analyzed the safety and efficacy of sevelamer compared to placebo, calcium carbonate (CC), or lanthanum carbonate (LC) in the treatment of chronic kidney disease (CKD) patients. A meta-analysis of 34 randomized controlled trials (RCTs) involving 2802 patients showed that sevelamer reduced all-cause mortality and vascular calcification score, and induced less hypercalcemia and hyperphosphatemia compared to Ca-based binders in CKD5D individuals. However, there were no significant differences in gastrointestinal adverse events (GAEs) incidence.
Article
Multidisciplinary Sciences
Honglei Hu, Xiaodong Zhao, Xingqian Jin, Shujuan Wang, Wenlong Liang, Xiangguo Cong
Summary: Eplerenone treatment has significant therapeutic effects on patients with diabetic nephropathy, reducing levels of urine protein, systolic blood pressure, and renal fibrosis indicator, without increasing adverse events.